Ingenza enables Scottish SME to bring low-cost haemophilia A treatment a step closer to market

Ingenza has delivered a new, proprietary biomanufacturing process for human recombinant factor VIII (rhFVIII) to Scottish biotechnology company ProFactor Pharma Ltd (PFP), which will considerably increase global access to low-cost treatment for haemophilia A. The novel bioprocess underpins PFP’s recent…